Continuation of Basic Research on TLM-007
First written in FY2022. 2 of 4 entries say "Advanced", first in FY2024. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「Subject enrollment has also been completed in the specified clinical research study of TLM-007, a project developing a glaucoma eye drop with an expanded indication as an eye drop to prevent myopia progression.」
For TLM-007, the company reports the milestone of completing subject enrollment in the domestic specified clinical research study initiated in February 2024. - FY2024AdvancedAnnual report
「TLM-007, a drug to suppress myopia progression, has been undergoing a small-scale specified clinical research study in Japan since February 2024.」
TLM-007 progressed from the basic research stage to a domestic specified clinical research study initiated in February 2024. - FY2023RestatedAnnual report
「Although the project is still at the basic research stage, we will continue research as another pipeline candidate for an eye drop to suppress myopia progression.」
TLM-007 continues as a pipeline candidate for an eye drop to suppress myopia progression at the basic research stage. - FY2022First statedAnnual report
「Although the project is still at the basic research stage, we will continue research as another pipeline candidate for an eye drop to suppress myopia progression.」
The myopia-suppression drug based on an expanded indication for a glaucoma eye drop continues as a pipeline project at the basic research stage.